Bioengineered Cardiac Tissue for Hypoplastic Left Heart Syndrome Analysis


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 10-006845
    Sponsor Protocol Number: 10-006845

About this study

The purpose of this study is to produce and characterize patient-specific cardiac tissue for Hypoplastic Left Heart Syndrome (HLHS) using reprogrammed cell technology.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Patients age 0-100 yrs. with clinically diagnosed hypoplastic left heart syndrome (HLHS) undergoing planned surgical repair and unaffected adult biological parents and/or siblings.

Exclusion Criteria:

  • Subjects with allergy to subcutaneous lidocaine, bupivicaine, or epinephrine. 


Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Timothy Nelson, M.D., Ph.D.

Open for enrollment

Contact information:

Lucas Timmons


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available